



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 47665

Title: The rise of Sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease

Reviewer's code: 02926997

Reviewer's country: Iran

Science editor: Li-Jun Cui

Reviewer accepted review: 2019-03-30 20:10

Reviewer performed review: 2019-04-06 10:04

Review time: 6 Days and 13 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Dear author, The role of "sodium-glucose cotransporter 2 inhibitors" in the management of NASH is newly come into interest. Please define the search strategy and inclusion and exclusion criteria of reported researches. Please highlight the unique



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

features of the mentioned medications in the NASH treatment.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No



PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 47665

Title: The rise of Sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease

Reviewer's code: 00050195

Reviewer's country: Israel

Science editor: Li-Jun Cui

Reviewer accepted review: 2019-05-10 02:11

Reviewer performed review: 2019-05-18 19:31

Review time: 8 Days and 17 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good		<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	(General priority)	Peer-reviewer's expertise on the topic of the manuscript:
<input type="checkbox"/> Grade E: Do not publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Minor revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> General
		<input type="checkbox"/> Rejection	<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The authors are to be congratulated for providing this important review. NAFLD is now the major cause of cirrhosis and its complications in Western countries. It is the hepatic manifestation of the metabolic syndrome. There is a clear link to diabetes mellitus and



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

this is a significant prognostic factor. The authors are right to give prominence to the fact that weight loss and lifestyle changes are the most effective therapy and that pharmacologic therapies have poor quality of evidence supporting their use. The authors present an accurate review of the use of metformin, thiazolidinediones, and incretin-based therapy which do not have good quality evidence linking their use to an improvement in the outcome of NAFLD. The SGLT-2 inhibitors have been proven to prevent clinical end-points in DM and are a promising tool for treating NAFLD. The authors provide a comprehensive review of the subject. I think the manuscript should be accepted as is and have no significant criticisms to make.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- The same title
- Duplicate publication
- Plagiarism
- No

BPG Search:

- The same title
- Duplicate publication
- Plagiarism
- No